October 7, 2024 02:44 PM EDT
Pharma
Law

Supreme Court de­clines to re­view patent bat­tle over in­hala­tion pow­der Yutrepia

Katherine Lewin

News Reporter

Liq­uidia’s stock $LQ­DA rose about 10% on Mon­day fol­low­ing a win in the US Supreme Court for its tre­pros­tinil in­hala­tion pow­der Yutrepia.

Liq­uidia has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Spe­cial re­port 2024: Meet 20 women break­ing new ground in bio­phar­ma R&D

No­vo and Vi­a­tris set­tle Ozem­pic patent suit as gener­ic en­try date re­mains un­known

Post-Hoc: What does an ac­tivist want with Pfiz­er?

Pfiz­er tar­get­ed by ac­tivist, fol­low­ing post-pan­dem­ic stum­bles — re­ports

As­traZeneca makes an­oth­er car­dio deal, bet­ting $100M on Chi­na com­pa­ny’s lipid drug

Ju­do Bio launch­es with $100M for kid­ney-tar­get­ed siR­NA ther­a­pies

A service from the Financial Times